Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Published:2016-09-23 Issue: Volume: Page:now185
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:NEUONC

Author:

Batchelor Tracy T.,Gerstner Elizabeth R.,Ye Xiaobu,Desideri Serena,Duda Daniel G.,Peereboom David,Lesser Glenn J.,Chowdhary Sajeel,Wen Patrick Y.,Grossman Stuart,Supko Jeffrey G.

Funder

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/19/4/567/17697111/now185.pdf

Reference31 articles.

1. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Standards of care for treatment of recurrent glioblastoma—are we there yet?

4. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

5. PDGF and PDGF receptors in glioma

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling;Cells;2024-03-11

2. Targeted Glioma Therapy—Clinical Trials and Future Directions;Pharmaceutics;2024-01-11

3. Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma;Brain Communications;2024

4. Druggable genomic landscapes of high-grade gliomas;Frontiers in Medicine;2023-12-08

5. The role of angiogenic growth factors in the immune microenvironment of glioma;Frontiers in Oncology;2023-09-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3